Nuevas perspectivas en el tratamiento paliativo del glioblastoma multiforme y astrocitoma anaplásico recidivado con implantes de carmustina / New prospects of the paliative treatment of relapsing glioblastoma multiforme and anaplastic astrocytoma with carmustine implants

Analizamos el tratamiento de las recidivas de glioblastoma multiforme y astrocitoma anaplásico con cirugíamás la implantación de polímeros de carmustina (BCNU) en el lecho de la recidiva, con el objetivo de mejorarla calidad de vida, los síntomas neurológicos y generales, y aumentar el control tumoral. Reflejamos la experienciay datos clínicos de 4 pacientes intervenidos.El empleo de carmustina implantes puede realizarse de forma factible sin objetivarse efectos adversos queinterfieran la calidad de vida, además de observar un enlentecimiento en la progresión del deterioro neurológicode los pacientes.La selección de pacientes jóvenes, con un buen performance estatus, en los que se prevea la mejor resecciónde la recidiva posible, garantizará el éxito en el tratamiento paliativo con implantes de carmostina

In recurrent glioblastoma multiforme and anaplastic astrocytoma, surgery and carmustine (NCNU) polymersimplants over the surgical area of the removed recidivation is a promising way to improve the quality of life,the neurologic and general symptoms, and the tumor control. We report our data and experience in fourpatients. The resection was optimized because the patients were young and showed a performance statusbetween 0 and 2

[Multiple primaries of the upper aerodigestive tract, esophagus, and lung]. / Múltiples primarios en vías aerodigestivas superiores, esófago y pulmón.

The existence of multiple primary tumors of the upper aerodigestive tract, esophagus, and lung (UADT-E-L) is related with a common etiopathogenic factor (alcohol-tobacco association). In a review of 43 patients, 6.75% with a UADT-E-L tumor developed another neoplasm, 3.25% at the same site. Nine percent (8.59%) of the tumors were synchronic and 10.85% were metachronic. The most frequent association was larynx-lung. Another neoplasm was detected by physical examination and/or radiology in 44.18% of cases, with a time lapse of less than 3 years in 50%. The most frequent treatment was surgery with/without complementary radiotherapy. The most common stage was T1-T2 (62.06%) and N0-N1 (68.96%). The survival rate was 31% at 2 years and 25% at 3 years.